Understanding vaccine safety information from the vaccine adverse event reporting system

被引:292
|
作者
Varricchio, F [1 ]
Iskander, J
Destefano, F
Ball, R
Pless, R
Braun, MM
Chen, RT
机构
[1] Food & Drug Adm, Ctr Biol Evaluat & Res, Off Biostat & Epidemiol, Div Epidemiol, Ottawa, ON, Canada
[2] CDCP, Natl Immunizat Program, Epidemiol & Surveillance Div, Immunizat Safety Branch, Ottawa, ON, Canada
[3] Hlth Canada, Ctr Infect Dis Prevent & Control, Immunizat & Resp Infect Div, Immunizat Safety Unit, Ottawa, ON K1A 0L2, Canada
关键词
adverse event; vaccine; vaccine adverse event reporting system (VAERS);
D O I
10.1097/00006454-200404000-00002
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The Vaccine Adverse Event Reporting System (VAERS) is administered by the Food and Drug Administration and CDC and is a key component of postlicensure vaccine safety surveillance. Its primary function is to detect early warning signals and generate hypotheses about possible new vaccine adverse events or changes in frequency of known ones. VAERS is a passive surveillance system that relies on physicians and others to voluntarily submit reports of illness after vaccination. Manufacturers are required to report all adverse events of which they become aware. There are a number of well-described limitations of such reporting systems. These include, for example, variability in report quality, biased reporting, underreporting and the inability to determine whether a vaccine caused the adverse event in any individual report. Strengths of VAERS are that it is national in scope and timely. The information in VAERS reports is not necessarily complete nor is it verified systematically. Reports are classified as serious or nonserious based on regulatory criteria. Reports are coded by VAERS in a uniform way with a limited number of terms using a terminology called COSTART. Coding is useful for search purposes but is necessarily imprecise. VAERS is useful in detecting adverse events related to vaccines and most recently was used for enhanced reporting of adverse events in the national smallpox immunization campaign. VAERS data have always been publicly available. However, it is essential for users of VAERS data to be fully aware of the strengths and weaknesses of the system. VAERS data contain strong biases. Incidence rates and relative risks of specific adverse events cannot be calculated. Statistical significance tests and confidence intervals should be used with great caution and not routinely. Signals detected in VAERS should be subjected to further clinical and descriptive epidemiologic analysis. Confirmation in a controlled study is usually required. An understanding of the system's defined objectives and inherent drawbacks is vital to the effective use of VAERS data in vaccine safety investigations.
引用
收藏
页码:287 / 294
页数:8
相关论文
共 50 条
  • [1] Postmarketing safety surveillance of quadrivalent recombinant influenza vaccine: Reports to the vaccine adverse event reporting system
    Woo, Emily Jane
    Moro, Pedro L.
    VACCINE, 2021, 39 (13) : 1812 - 1817
  • [2] Postmarketing safety surveillance of trivalent recombinant influenza vaccine: Reports to the Vaccine Adverse Event Reporting System
    Woo, Emily Jane
    Moro, Pedro L.
    Cano, Maria
    Jankosky, Christopher
    VACCINE, 2017, 35 (42) : 5618 - 5621
  • [3] A review of the Vaccine Adverse Event Reporting System database
    Geier, DA
    Geier, MR
    EXPERT OPINION ON PHARMACOTHERAPY, 2004, 5 (03) : 691 - 698
  • [4] Developmental regression and autism reported to the vaccine adverse event reporting system
    Woo, Emily Jane
    Ball, Robert
    Landa, Rebecca
    Zimmerman, Andrew W.
    Braun, M. Miles
    AUTISM, 2007, 11 (04) : 301 - 310
  • [5] Chorioamnionitis following vaccination in the Vaccine Adverse Event Reporting System
    Datwani, Hema
    Moro, Pedro L.
    Harrington, Theresa
    Broder, Karen R.
    VACCINE, 2015, 33 (27) : 3110 - 3113
  • [6] Tracking vaccine lot lifecycles using reports to the vaccine adverse event reporting system (VAERS)
    Dayan, GH
    Iskander, J
    Glasser, J
    English-Bullard, R
    Fullerton, KE
    Chen, R
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2005, 14 (10) : 671 - 676
  • [7] The reporting sensitivity of the Vaccine Adverse Event Reporting System (VAERS) for anaphylaxis and for Guillain-Barre syndrome
    Miller, Elaine R.
    McNeil, Michael M.
    Moro, Pedro L.
    Duffy, Jonathan
    Su, John R.
    VACCINE, 2020, 38 (47) : 7458 - 7463
  • [8] Post-licensure safety surveillance of zoster vaccine live (Zostavax®) in the United States, Vaccine Adverse Event Reporting System (VAERS), 2006-2015
    Miller, Elaine R.
    Lewis, Paige
    Shimabukuro, Tom T.
    Su, John
    Moro, Pedro
    Woo, Emily Jane
    Jankosky, Christopher
    Cano, Maria
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2018, 14 (08) : 1963 - 1969
  • [9] Summary of COVID-19 vaccine-related reports in the vaccine adverse event reporting system
    Ceacareanu, Alice
    Wintrob, Zachary
    JOURNAL OF RESEARCH IN PHARMACY PRACTICE, 2021, 10 (03) : 107 - 113
  • [10] Safety of 9-valent human papillomavirus vaccine administration among pregnant women: Adverse event reports in the Vaccine Adverse Event Reporting System (VAERS), 2014-2017
    Landazabal, Claudia S.
    Moro, Pedro L.
    Lewis, Paige
    Omer, Saad B.
    VACCINE, 2019, 37 (09) : 1229 - 1234